HealthDay News — Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease, according to a study...
A new study by researchers from Arizona State University and their colleagues highlights a dietary strategy for significant health improvement and weight management. Participants following an...
The use of semaglutide for non-diabetic obese patients with cardiovascular disease was first reported to be associated with significant benefit in the SELECT trial, where major...